Skip to main content
Premium Trial:

Request an Annual Quote

New Products: HTG Molecular's Edge DMPK and TOA Assays

Premium

Tucson, Ariz.-based HTG Molecular Diagnostics this week announced the availbility of two new multiplexed assays for drug and oncology research.

The 47-gene Edge DMPK Assay enables researchers to characterize drug metabolism in pre-clinical studies. The company also released its Edge TOA Assay, which measures the expression levels of 32 of the most commonly assayed oncogenes in fresh or fixed biological specimens.

Both new offerings rely on HTG's quantitative nuclease protection assay, or qNPA, technology, and are processed using its automated Edge system for gene expression profiling of formalin-fixed, paraffin-embedded samples.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.